Key Highlights

  • Revenue was USD 1.8 million versus a USD 2.80 million estimate; none last year.
  • Gross profit was USD 324 thousand on cost of revenues of USD 1.5 million.
  • Loss from continuing operations was USD 1.9 million; discontinued operations lost USD 13.3 million.
  • Net loss reached USD 15.1 million versus USD 2.3 million a year earlier.

First Revenue Arrives

Flyte Aviation, Inc. (NYSE American:VJET), formerly "known as Catheter Precision", reported third-quarter revenue of USD 1.8 million with no revenue in the prior-year quarter, against an estimate of USD 2.80 million. Cost of revenues was USD 1.5 million, leaving Gross Profit of USD 324 thousand. Nine-month revenue was USD 2.8 million with gross profit of USD 347 thousand.

The company was incorporated in California in 2002 as Ra Medical Systems, reincorporated in Delaware in 2018 and originally developed an excimer laser platform for vascular and dermatological conditions.

Operating Costs and Discontinued Operations

Selling, general and administrative expense was USD 2.8 million versus USD 1.2 million, producing an operating loss of USD 2.5 million versus USD 1.2 million. Other income, net, was USD 140 thousand, including USD 162 thousand of gains on marketable securities and USD 206 thousand from a change in a deferred stock issuance liability. An income tax benefit of USD 463 thousand reduced the loss from continuing operations to USD 1.9 million from USD 1.2 million.

Loss from discontinued operations, net of tax, was USD 13.3 million versus USD 1.1 million. The filing attributes the increase primarily to a non-cash Impairment of Assets held for sale. Net loss was USD 15.1 million versus USD 2.3 million.

Nine-Month Results and Liquidity

For the nine months, selling, general and administrative expense was USD 6.9 million versus USD 3.5 million, and the prior year included USD 2.0 million of acquired in-process research and development. Loss from continuing operations was USD 4.7 million versus USD 3.9 million, other income included a USD 3.2 million change in deferred consideration and a USD 2.3 million charge on a minority Equity interest, and net loss was USD 20.1 million versus USD 11.8 million.

At September 30, 2026, cash and cash equivalents were USD 2.4 million, up from USD 88 thousand at year-end, and the filing reports a substantial accumulated deficit. Intangible assets were USD 4.0 million and operating Lease right-of-use assets USD 2.2 million. The financial statements carry a Going Concern disclosure, noting substantial doubt about the company's ability to continue.

The Balance Sheet at September 30 showed total current assets of USD 3.8 million versus USD 390 thousand at year-end, prepaid expenses of USD 1.2 million versus USD 61 thousand, property and equipment of USD 141 thousand, operating lease right-of-use assets of USD 2.2 million and intangible assets of USD 4.0 million. Interest expense was USD 121 thousand, plus USD 44 thousand to related parties.

Factors to Watch

The filing's reference points include revenue progression from the new business, operating expenses after the acquisition-related build, the carrying value of assets held for sale and the funding needed to address the going concern disclosure.